{'fraction_non_alphanumeric': 0.015467904098994586, 'fraction_numerical': 0.006187161639597835, 'mean_word_length': 5.075117370892019, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Tumescent liposuction in the treatment of partial hemifacial hypertrophy.

Hemihypertrophy or hemihyperplasia is a rare developmental phenomenon first described by Meckel in 1822 and then by Wagner in 1839. It may be located on an entire side or an isolated part of one side of the body. This condition frequently involves all tissues or may be limited to a specific one in the affected site, as in myohyperplasia, in which only the musculature is involved. The deformity is usually present at birth and gradually but steadily progresses with time, finally leading to asymmetries in various parts of the body. Rowe classified hemifacial hypertrophy (HH), a specific entity of hemihypertrophy, as true and partial, and Ward and Lerner classified it as total and limited according to the amount of involved structures, with true or total type describing hyperplasia of all tissues of the face, and partial or limited type involving only one structure. The prognosis and response to the surgery is generally better in the latter than in the former, with no recurrence expected after effective treatment of the involved tissue, although cosmetic outcomes frequently present limited to moderate gains. No formal case of malignant degeneration associated with HH has been reported in the literature.